gdc
Breast CancerFDA Approvals, News & UpdatesNewsworthy

Verzenio a New Targeted Therapy Approved for Metastatic Breast Cancer

Read about Verzenio, which was approved by the FDA in 2017, in combination with fulvestrant, for treatment of women with HR-positive, HER2-positive, HER2-negative advanced, or metastatic breast cancer that progressed after endocrine therapy.
December 2017 Vol 3 No 6

On September 28, 2017, the FDA approved Verzenio (abemaciclib; from Eli Lilly), a CDK4/CDK6 inhibitor, in combination with fulvestrant, for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy, as well as for use alone in patients whose metastatic breast cancer progressed after endocrine therapy and after previous use of chemotherapy in the metastatic setting.

“Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class, it can be given as a stand-alone treatment to patients who were previously treated with endocrine therapy and chemotherapy,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approved Verzenio for these 2 uses based on clinical trials showing its benefits for patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The most common side effects with Verzenio are diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, and thrombocytopenia.

Share this:

Recommended For You
Breast CancerPatient Stories
My Story: Male Breast Cancer and Waldenström's Macroglobulinemia
By Edward J. Sawa
Edward Sawa was waking up with headaches that disrupted his daily activities and ended up being diagnosed with Waldenström’s macroglobulinemia and breast cancer. Read the lessons he’s learned as a male with breast cancer.
Breast CancerFDA Approvals, News & Updates
FDA Approved Margenza for Patients with Metastatic HER2-Positive Breast Cancer
In December 2020, the FDA approved Margenza (margetuximab-cmkb), a new targeted therapy, for the treatment of patients with metastatic HER2-positive breast cancer, representing an important new option for patients with this type of breast cancer that continues to progress despite different treatments.
FDA Approvals, News & UpdatesLung Cancer
FDA Approves Tepmetko, New Targeted Therapy, for Patients with Metastatic Lung Cancer and MET Exon 14 Alterations
In February 2021, the FDA approved Tepmetko (tepotinib), a new oral targeted therapy, for the treatment of all adults with metastatic non–small-cell lung cancer and MET exon 14 alterations. Tepmetko is the first MET inhibitor that has been approved by the FDA.
FDA Approvals, News & UpdatesLung Cancer
Tagrisso Approved as Adjuvant Therapy for Patients with Lung Cancer and EGFR Mutations
In December 2020, the FDA approved Tagrisso (osimertinib) for adjuvant therapy (continued therapy to prevent cancer recurrence) after surgical removal of the tumor, in patients with non–small-cell lung cancer and EGFR exon 19 deletions or exon 21 L858R mutations. Tagrisso was previously approved for the treatment of other types of lung cancer.
Last modified: March 25, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country